The role for saxagliptin within the management of type 2 diabetes mellitus: An update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Aschner, Pablo J ^a,b  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b HOSPITAL UNIVERSITARIO SAN IGNACIO   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ADD ON THERAPY; CELL VOLUME; CREATININE CLEARANCE; DISEASE DURATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH SURVEY; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT ATTITUDE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STREPTOZOCIN DIABETES; UNSPECIFIED SIDE EFFECT;

EID: 78650070616     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-69     Document Type: Review

References (9)

1. Efficacy of saxagliptin according to patient baseline characteristics: a pooled analysis of three add-on pivotal randomised phase 3 clinical trials. E Allen M Donovan N Berglind P Maheux, EASD 2010 826-P
2. Efficacy of saxagliptin in relation to baseline HbA1c in a pooled analysis of three add-on pivotal randomised phase 3 clinical trials. P Maheux M Donovan E Allen N Berglind H Bouzamondo, EASD 2010 825-P
3. Saxagliptin is non-inferior to glipizide when added to metformin in patients with type 2 diabetes mellitus. B Göke B Gallwitz J Eriksson A Hellqvist I Gause-Nilsson, ADA 2010 578-P
4. Saxagliptin initial combination with metformin provides sustained glycemic control and is well tolerated in patients with type 2 diabetes: 76-week results. A Pfützner E Paz-Pacheo N Berglind E Allen B Frederich B Chen, ADA 2010 64-OR
5. Exposure modeling of Saxagliptin and 5-Hydroxy Saxagliptin in healthy subjects and in patients with type 2 diabetes to support Saxagliptin dosing recommendations. L Zhang DW Boulton M Pfister, ADA 2010 675-P
6. Saxagliptin improves glycemic control and is well tolerated in patients with type 2 diabetes mellitus (T2DM) and renal impairment compared with placebo. M Nowicki I Rychlik H Haller ML Warren L Suchower I Gausenilsson, ADA 2010 550-P
7. Preservation of pancreatic beta cell mass in high fat-fed STZ treated mice by the Dipeptidyl peptidase-4 inhibitors saxagliptin and sitagliptin. SM Poucher J Francis S Vickers S Cheetham G Birmingham K Dickinson B Zinker A Bellamine M Kirby, EASD 2010 567-P
8. The PANORAMA pan-European survey: glycaemic control and treatment patterns in patients with type 2 diabetes. P de Pablos-Velasco C Bradley E Eschwège L Gönder-Frederick K Parhofer H Vandenberghe D Simon, EASD 2010 1012-P
9. The PANORAMA pan-European Survey: Impact of severe and non-severe hypoglycaemia on quality of life and other patient reported outcomes in patients with type 2 diabetes. C Bradley E Eschwège P de Pablos-Velasco K Parhofer D Simon M Tafalla E Pascual L Gönder-Frederick, EASD 2010 580-P